← Back to headlines
Pfizer Extends Patent Life for Rare Disease Drug
Pfizer has secured deals to extend the patent life for one of its top-selling rare disease drugs, ensuring continued market exclusivity.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
